换一批The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
第一作者：
E,Terpos
第一单位：
Department of Hematology and Medical Research, 251 General Air Force Hospital, Athens, Greece. eterpos@hotmail.com
作者：
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药, 烷基化(Antineoplastic Agents, Alkylating);抗肿瘤药, 激素(Antineoplastic Agents, Hormonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);骨重建(Bone Remodeling);骨和骨组织(Bone and Bones);硼酸化物(Boronic Acids);细胞因子类(Cytokines);地塞米松(Dexamethasone);女(雌)性(Female);人类(Humans);免疫抑制剂(Immunosuppressive Agents);男(雄)性(Male);美法仑(Melphalan);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);新生血管化, 生理性(Neovascularization, Physiologic);吡嗪类(Pyrazines);复发(Recurrence);存活率(Survival Rate);沙立度胺(Thalidomide)
DOI
10.1038/leu.2008.235
PMID
18769451
发布时间
2015-11-19
- 浏览8
Leukemia
2247-56页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
